FSMA Fee Technical Corrections Act

1) What happened and status: Senator Durbin (D-IL) introduced S.3252 on November 20, 2025, a technical corrections bill adjusting the fee methodology under the FDA Food Safety Modernization Act. It was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions. The bill has 2 cosponsors (Blumenthal and Markey) and no companion House bill. It remains in early-stage with no committee markup or floor votes. 6 months with no further action indicates low legislative priority. 2) The money trail: This bill does not authorize or appropriate any federal spending. It sets user fee methodology—FDA will collect up to $15,000 per reinspection or recall event from regulated food facilities, starting FY2026. These are fee-for-service charges, not government expenditures. The Congressional Budget Office would score this as a net zero or negligible revenue offset. Small businesses (defined by FDA) receive a one-third reduction. 3) Structural winners and losers: No structural winners. The bill is purely procedural—correcting legislative language to allow FDA to assess fees previously authorized. Large-cap food manufacturers (GIS, CAG, CPB, HSY, MKC, SJM) are nominally the obligated parties, but the $15,000 fee per event is immaterial for companies with $6B-$19B in annual revenue. A single reinspection fee represents 0.00008% to 0.00025% of revenue. The bill does not change FDA inspection frequency, recall authority, or food safety standards—only the fee collection mechanism. 4) Real market data analysis: The 30-day price action for all named tickers shows significant declines (GIS -5.83%, CAG -9.35%, CPB -7.45%, HSY -11.38%, MKC -0.02%, SJM +1.12%). HSY's -11.38% decline is the most severe, likely driven by cocoa cost inflation and consumer demand weakness, not legislative risk. SJM's +1.12% is a modest outlier. None of these moves correlate with S.3252—the bill was introduced 5 months before the data period and has not advanced. The sectorwide pressure reflects macro consumer staples headwinds. 5) Timeline: The bill has not moved since November 2025. For it to become law, it must pass committee markup, Senate floor vote, House introduction and passage (no companion bill exists), and presidential signature. Given the narrow technical scope and absence of urgency, passage in the 119th Congress is uncertain. Even if enacted, FY2026 fees take effect the following October—an additional 5+ months away. No near-term market catalyst.